Raj Wadwa
Concepts (327)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 128 | 2025 | 3709 | 8.360 |
Why?
| | Insulin Infusion Systems | 45 | 2025 | 393 | 4.780 |
Why?
| | Blood Glucose | 69 | 2025 | 2180 | 3.690 |
Why?
| | Insulin | 51 | 2025 | 2399 | 3.610 |
Why?
| | Hypoglycemic Agents | 51 | 2025 | 1281 | 3.370 |
Why?
| | Blood Glucose Self-Monitoring | 43 | 2025 | 638 | 2.920 |
Why?
| | Pancreas, Artificial | 18 | 2025 | 84 | 2.330 |
Why?
| | Hypoglycemia | 27 | 2025 | 443 | 2.240 |
Why?
| | Diabetic Angiopathies | 16 | 2019 | 258 | 1.610 |
Why?
| | Vascular Stiffness | 14 | 2019 | 493 | 1.490 |
Why?
| | Cardiovascular Diseases | 25 | 2019 | 2108 | 1.420 |
Why?
| | Adolescent | 101 | 2025 | 21463 | 1.300 |
Why?
| | Child | 77 | 2025 | 21968 | 1.070 |
Why?
| | Telemedicine | 3 | 2022 | 847 | 0.890 |
Why?
| | Albuminuria | 4 | 2019 | 185 | 0.890 |
Why?
| | Diabetes Mellitus, Type 2 | 11 | 2020 | 2512 | 0.850 |
Why?
| | Young Adult | 55 | 2025 | 13126 | 0.820 |
Why?
| | Hyperglycemia | 11 | 2022 | 346 | 0.810 |
Why?
| | Humans | 143 | 2025 | 136783 | 0.740 |
Why?
| | Dyslipidemias | 4 | 2019 | 176 | 0.730 |
Why?
| | Male | 98 | 2025 | 67361 | 0.690 |
Why?
| | Female | 100 | 2025 | 72840 | 0.670 |
Why?
| | Biosensing Techniques | 2 | 2020 | 126 | 0.670 |
Why?
| | Uromodulin | 1 | 2019 | 21 | 0.630 |
Why?
| | Glycopeptides | 1 | 2019 | 43 | 0.620 |
Why?
| | Insulin Lispro | 4 | 2022 | 39 | 0.550 |
Why?
| | Carotid Intima-Media Thickness | 3 | 2018 | 91 | 0.550 |
Why?
| | Ketones | 2 | 2016 | 49 | 0.530 |
Why?
| | Diabetic Ketoacidosis | 6 | 2024 | 202 | 0.530 |
Why?
| | Self-Management | 3 | 2024 | 166 | 0.520 |
Why?
| | Child, Preschool | 20 | 2024 | 11069 | 0.500 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 442 | 0.500 |
Why?
| | Biomarkers | 10 | 2020 | 4158 | 0.490 |
Why?
| | Autonomic Nervous System | 3 | 2013 | 75 | 0.490 |
Why?
| | Algorithms | 12 | 2024 | 1686 | 0.470 |
Why?
| | Adult | 56 | 2025 | 37616 | 0.470 |
Why?
| | Cholesterol | 6 | 2020 | 410 | 0.470 |
Why?
| | Remote Consultation | 1 | 2015 | 50 | 0.460 |
Why?
| | Diabetic Nephropathies | 5 | 2019 | 293 | 0.450 |
Why?
| | Patient Compliance | 2 | 2015 | 576 | 0.440 |
Why?
| | Calcinosis | 4 | 2014 | 235 | 0.420 |
Why?
| | Monitoring, Ambulatory | 4 | 2020 | 87 | 0.410 |
Why?
| | Cystatin C | 2 | 2015 | 65 | 0.390 |
Why?
| | Diagnostic Techniques, Cardiovascular | 2 | 2014 | 11 | 0.390 |
Why?
| | Patient Education as Topic | 4 | 2019 | 760 | 0.390 |
Why?
| | Case-Control Studies | 13 | 2020 | 3537 | 0.370 |
Why?
| | Triglycerides | 9 | 2022 | 524 | 0.360 |
Why?
| | Glucagon | 3 | 2016 | 109 | 0.360 |
Why?
| | Arteries | 2 | 2010 | 268 | 0.350 |
Why?
| | Risk Factors | 27 | 2019 | 10331 | 0.350 |
Why?
| | Insulin Aspart | 3 | 2022 | 27 | 0.350 |
Why?
| | Reproducibility of Results | 9 | 2024 | 3272 | 0.350 |
Why?
| | Quality of Life | 6 | 2024 | 2868 | 0.340 |
Why?
| | Graves Disease | 1 | 2010 | 34 | 0.340 |
Why?
| | Adipose Tissue | 3 | 2022 | 629 | 0.320 |
Why?
| | Body Mass Index | 11 | 2024 | 2364 | 0.320 |
Why?
| | Friedreich Ataxia | 1 | 2010 | 75 | 0.310 |
Why?
| | Cholesterol, LDL | 4 | 2014 | 366 | 0.300 |
Why?
| | Diabetes Complications | 2 | 2007 | 226 | 0.300 |
Why?
| | Glomerular Filtration Rate | 4 | 2019 | 744 | 0.290 |
Why?
| | Middle Aged | 33 | 2024 | 33200 | 0.290 |
Why?
| | Vascular Diseases | 2 | 2013 | 244 | 0.290 |
Why?
| | Psychometrics | 3 | 2021 | 721 | 0.290 |
Why?
| | Hyperlipidemias | 2 | 2007 | 120 | 0.280 |
Why?
| | Skiing | 2 | 2019 | 46 | 0.280 |
Why?
| | Pulse Wave Analysis | 10 | 2019 | 269 | 0.280 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1568 | 0.270 |
Why?
| | Insulin Resistance | 6 | 2019 | 1201 | 0.250 |
Why?
| | Calibration | 4 | 2019 | 145 | 0.250 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 66 | 0.240 |
Why?
| | Coronary Artery Disease | 3 | 2007 | 702 | 0.240 |
Why?
| | Apolipoproteins B | 1 | 2014 | 43 | 0.230 |
Why?
| | Self Report | 2 | 2020 | 825 | 0.230 |
Why?
| | Blood Pressure | 7 | 2014 | 1772 | 0.220 |
Why?
| | Exercise | 5 | 2019 | 2038 | 0.220 |
Why?
| | Cross-Over Studies | 7 | 2024 | 560 | 0.210 |
Why?
| | Heart Rate | 5 | 2019 | 823 | 0.210 |
Why?
| | Infusion Pumps, Implantable | 2 | 2020 | 25 | 0.210 |
Why?
| | Uric Acid | 2 | 2015 | 163 | 0.210 |
Why?
| | Adiponectin | 4 | 2012 | 243 | 0.210 |
Why?
| | Diabetes Mellitus | 4 | 2025 | 1033 | 0.200 |
Why?
| | Pilot Projects | 2 | 2020 | 1697 | 0.200 |
Why?
| | Diabetic Neuropathies | 3 | 2019 | 93 | 0.200 |
Why?
| | Blood Vessels | 2 | 2018 | 187 | 0.200 |
Why?
| | Cholesterol, HDL | 4 | 2014 | 203 | 0.190 |
Why?
| | Insulin, Regular, Human | 4 | 2023 | 43 | 0.190 |
Why?
| | Kidney | 3 | 2022 | 1463 | 0.190 |
Why?
| | Adiposity | 2 | 2018 | 518 | 0.180 |
Why?
| | Computer Systems | 2 | 2018 | 44 | 0.180 |
Why?
| | Lipids | 3 | 2014 | 665 | 0.180 |
Why?
| | Hypertension | 4 | 2019 | 1284 | 0.180 |
Why?
| | Age Factors | 9 | 2016 | 3290 | 0.180 |
Why?
| | Technology | 1 | 2022 | 96 | 0.180 |
Why?
| | Follow-Up Studies | 9 | 2023 | 5115 | 0.180 |
Why?
| | Guideline Adherence | 2 | 2015 | 543 | 0.170 |
Why?
| | Glycosides | 1 | 2021 | 37 | 0.170 |
Why?
| | Cohort Studies | 11 | 2017 | 5718 | 0.170 |
Why?
| | Treatment Outcome | 12 | 2025 | 10764 | 0.170 |
Why?
| | Microvessels | 2 | 2018 | 85 | 0.170 |
Why?
| | Adolescent Behavior | 2 | 2017 | 534 | 0.170 |
Why?
| | Coronary Vessels | 2 | 2014 | 245 | 0.160 |
Why?
| | Patient Dropouts | 1 | 2020 | 67 | 0.160 |
Why?
| | Inpatients | 1 | 2024 | 499 | 0.160 |
Why?
| | Carotid Arteries | 2 | 2013 | 209 | 0.160 |
Why?
| | Brachial Artery | 3 | 2016 | 201 | 0.150 |
Why?
| | Sports | 2 | 2019 | 230 | 0.150 |
Why?
| | Administration, Intranasal | 2 | 2016 | 90 | 0.150 |
Why?
| | Prevalence | 6 | 2014 | 2712 | 0.150 |
Why?
| | Evidence-Based Medicine | 2 | 2014 | 738 | 0.150 |
Why?
| | Bacterial Vaccines | 1 | 1999 | 63 | 0.150 |
Why?
| | Cross-Sectional Studies | 8 | 2024 | 5417 | 0.150 |
Why?
| | Cardiotonic Agents | 1 | 2018 | 125 | 0.140 |
Why?
| | Biomedical Technology | 1 | 2018 | 43 | 0.140 |
Why?
| | Antihypertensive Agents | 3 | 2014 | 488 | 0.140 |
Why?
| | Pneumococcal Infections | 1 | 1999 | 115 | 0.140 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 170 | 0.140 |
Why?
| | Endocrinology | 1 | 2018 | 79 | 0.140 |
Why?
| | Caregivers | 1 | 2025 | 873 | 0.140 |
Why?
| | Ohio | 5 | 2015 | 154 | 0.140 |
Why?
| | Diabetic Cardiomyopathies | 2 | 2016 | 36 | 0.140 |
Why?
| | Infant | 7 | 2019 | 9442 | 0.140 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 27 | 0.140 |
Why?
| | Streptococcus pneumoniae | 1 | 1999 | 169 | 0.140 |
Why?
| | Hospitalization | 2 | 2024 | 2195 | 0.130 |
Why?
| | Regression Analysis | 4 | 2014 | 1024 | 0.130 |
Why?
| | Immunization | 1 | 1999 | 410 | 0.130 |
Why?
| | Proprotein Convertase 9 | 1 | 2017 | 73 | 0.130 |
Why?
| | Risk Assessment | 4 | 2014 | 3429 | 0.130 |
Why?
| | Sex Factors | 5 | 2016 | 2068 | 0.130 |
Why?
| | Aorta | 1 | 2018 | 417 | 0.120 |
Why?
| | Aged | 12 | 2023 | 23729 | 0.120 |
Why?
| | Wyoming | 1 | 2015 | 36 | 0.120 |
Why?
| | Coronary Disease | 3 | 2007 | 385 | 0.120 |
Why?
| | Perception | 1 | 2018 | 356 | 0.120 |
Why?
| | Meals | 3 | 2024 | 124 | 0.120 |
Why?
| | Periodontal Diseases | 1 | 2015 | 60 | 0.120 |
Why?
| | Colorado | 9 | 2017 | 4491 | 0.120 |
Why?
| | Automation | 2 | 2025 | 95 | 0.120 |
Why?
| | Hormones | 1 | 2015 | 142 | 0.120 |
Why?
| | Inflammation | 2 | 2018 | 2834 | 0.120 |
Why?
| | Pediatric Obesity | 2 | 2019 | 590 | 0.120 |
Why?
| | Videoconferencing | 1 | 2015 | 66 | 0.120 |
Why?
| | Lipoproteins | 2 | 2022 | 167 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2022 | 939 | 0.120 |
Why?
| | Metformin | 1 | 2018 | 329 | 0.120 |
Why?
| | Surveys and Questionnaires | 7 | 2021 | 5749 | 0.110 |
Why?
| | Self Care | 2 | 2014 | 375 | 0.110 |
Why?
| | Vascular Calcification | 1 | 2016 | 108 | 0.110 |
Why?
| | History, 21st Century | 2 | 2025 | 211 | 0.110 |
Why?
| | Patient Satisfaction | 1 | 2018 | 650 | 0.110 |
Why?
| | Consensus | 3 | 2023 | 679 | 0.110 |
Why?
| | History, 20th Century | 2 | 2025 | 323 | 0.110 |
Why?
| | Ketosis | 1 | 2014 | 12 | 0.110 |
Why?
| | Atherosclerosis | 3 | 2015 | 415 | 0.110 |
Why?
| | Sleep | 2 | 2022 | 751 | 0.110 |
Why?
| | Dietary Fiber | 1 | 2014 | 53 | 0.110 |
Why?
| | Creatinine | 2 | 2015 | 498 | 0.110 |
Why?
| | Pandemics | 1 | 2022 | 1619 | 0.100 |
Why?
| | Goals | 1 | 2015 | 168 | 0.100 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 267 | 0.100 |
Why?
| | Circadian Rhythm | 2 | 2015 | 465 | 0.100 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2019 | 615 | 0.100 |
Why?
| | Parents | 4 | 2022 | 1355 | 0.100 |
Why?
| | Bionics | 2 | 2022 | 12 | 0.100 |
Why?
| | Pediatrics | 2 | 2018 | 1112 | 0.100 |
Why?
| | Acetaminophen | 1 | 2015 | 268 | 0.100 |
Why?
| | Registries | 3 | 2020 | 2015 | 0.100 |
Why?
| | Prognosis | 6 | 2020 | 4018 | 0.100 |
Why?
| | Femoral Artery | 1 | 2013 | 179 | 0.100 |
Why?
| | Longitudinal Studies | 6 | 2016 | 2847 | 0.090 |
Why?
| | Obesity | 3 | 2020 | 2975 | 0.090 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 184 | 0.090 |
Why?
| | Kidney Function Tests | 1 | 2011 | 159 | 0.090 |
Why?
| | Precision Medicine | 1 | 2014 | 426 | 0.080 |
Why?
| | Injections, Subcutaneous | 2 | 2020 | 154 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 395 | 0.080 |
Why?
| | Hypolipidemic Agents | 2 | 2008 | 92 | 0.080 |
Why?
| | Thyroidectomy | 1 | 2010 | 106 | 0.080 |
Why?
| | Glycosuria | 1 | 2009 | 9 | 0.080 |
Why?
| | Infant, Newborn | 4 | 2019 | 6046 | 0.080 |
Why?
| | Blood Flow Velocity | 2 | 2010 | 412 | 0.080 |
Why?
| | Outpatients | 3 | 2021 | 393 | 0.080 |
Why?
| | United States | 8 | 2020 | 14660 | 0.080 |
Why?
| | Prospective Studies | 4 | 2025 | 7583 | 0.080 |
Why?
| | Double-Blind Method | 3 | 2021 | 1981 | 0.070 |
Why?
| | Combined Modality Therapy | 3 | 2017 | 1235 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Age Distribution | 2 | 2006 | 391 | 0.070 |
Why?
| | Equipment Design | 2 | 2019 | 522 | 0.070 |
Why?
| | Health Promotion | 1 | 2014 | 736 | 0.070 |
Why?
| | Life Style | 2 | 2008 | 484 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2007 | 118 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1043 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2023 | 1455 | 0.070 |
Why?
| | Mobile Applications | 2 | 2020 | 180 | 0.070 |
Why?
| | Cold Temperature | 2 | 2019 | 177 | 0.070 |
Why?
| | Fetal Distress | 1 | 2006 | 13 | 0.070 |
Why?
| | Disease Progression | 5 | 2018 | 2750 | 0.070 |
Why?
| | Catheter Ablation | 1 | 2010 | 349 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 84 | 0.060 |
Why?
| | Time Factors | 3 | 2014 | 6792 | 0.060 |
Why?
| | Apolipoproteins A | 1 | 2006 | 19 | 0.060 |
Why?
| | Polymorphism, Genetic | 2 | 2007 | 657 | 0.060 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 201 | 0.060 |
Why?
| | Smoking | 1 | 2014 | 1633 | 0.060 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2006 | 77 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1483 | 0.060 |
Why?
| | Postprandial Period | 2 | 2018 | 107 | 0.060 |
Why?
| | Seasons | 2 | 2019 | 544 | 0.060 |
Why?
| | Hypertrophy | 2 | 2016 | 132 | 0.060 |
Why?
| | Family Health | 1 | 2006 | 197 | 0.060 |
Why?
| | Linear Models | 3 | 2014 | 845 | 0.060 |
Why?
| | Infant, Newborn, Diseases | 1 | 2006 | 113 | 0.060 |
Why?
| | Radiography | 1 | 2007 | 829 | 0.060 |
Why?
| | Pregnancy in Diabetics | 1 | 2006 | 122 | 0.060 |
Why?
| | Glucose Intolerance | 1 | 2005 | 146 | 0.050 |
Why?
| | Sex Distribution | 1 | 2005 | 376 | 0.050 |
Why?
| | Cotinine | 1 | 2004 | 87 | 0.050 |
Why?
| | Hair | 1 | 2004 | 84 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2024 | 112 | 0.050 |
Why?
| | Feasibility Studies | 2 | 2018 | 947 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1129 | 0.050 |
Why?
| | Rats | 1 | 2012 | 5628 | 0.050 |
Why?
| | Inflammation Mediators | 1 | 2006 | 514 | 0.050 |
Why?
| | Retrospective Studies | 6 | 2024 | 15564 | 0.050 |
Why?
| | Hemodynamics | 2 | 2022 | 1110 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 379 | 0.050 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2022 | 19 | 0.050 |
Why?
| | Glucose | 2 | 2021 | 1019 | 0.050 |
Why?
| | Seizures | 1 | 2006 | 430 | 0.050 |
Why?
| | Incidence | 3 | 2014 | 2788 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2030 | 0.050 |
Why?
| | Societies, Medical | 2 | 2018 | 820 | 0.050 |
Why?
| | Reference Values | 2 | 2018 | 817 | 0.050 |
Why?
| | Tobacco Smoke Pollution | 1 | 2004 | 285 | 0.040 |
Why?
| | Motor Activity | 2 | 2018 | 719 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 584 | 0.040 |
Why?
| | Insulin-Secreting Cells | 1 | 2005 | 372 | 0.040 |
Why?
| | Sitosterols | 1 | 2020 | 2 | 0.040 |
Why?
| | Behavior Therapy | 1 | 2023 | 257 | 0.040 |
Why?
| | Phytosterols | 1 | 2020 | 12 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 73 | 0.040 |
Why?
| | Logistic Models | 1 | 2005 | 2060 | 0.040 |
Why?
| | Pancreas | 1 | 2022 | 328 | 0.040 |
Why?
| | Social Conditions | 1 | 2019 | 12 | 0.040 |
Why?
| | India | 1 | 2020 | 193 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2004 | 576 | 0.040 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2019 | 36 | 0.040 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 286 | 0.040 |
Why?
| | Vaccines, Conjugate | 1 | 1999 | 65 | 0.040 |
Why?
| | Anthropometry | 1 | 2019 | 213 | 0.040 |
Why?
| | Fear | 1 | 2022 | 338 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2021 | 210 | 0.040 |
Why?
| | Smartphone | 1 | 2019 | 91 | 0.040 |
Why?
| | Waist Circumference | 1 | 2018 | 143 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 192 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 198 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1059 | 0.040 |
Why?
| | Virginia | 1 | 2017 | 62 | 0.030 |
Why?
| | Accelerometry | 1 | 2018 | 98 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2017 | 763 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2019 | 230 | 0.030 |
Why?
| | Age of Onset | 1 | 2018 | 518 | 0.030 |
Why?
| | Magnetic Resonance Angiography | 1 | 2018 | 240 | 0.030 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 107 | 0.030 |
Why?
| | Vascular Capacitance | 1 | 2016 | 4 | 0.030 |
Why?
| | Powders | 1 | 2016 | 43 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 739 | 0.030 |
Why?
| | Food Preferences | 1 | 2017 | 119 | 0.030 |
Why?
| | Equipment Failure | 1 | 2016 | 108 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2016 | 126 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2024 | 1098 | 0.030 |
Why?
| | Nausea | 1 | 2016 | 111 | 0.030 |
Why?
| | Family | 1 | 2020 | 666 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 3566 | 0.030 |
Why?
| | Ankle Brachial Index | 1 | 2015 | 37 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 362 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2016 | 243 | 0.030 |
Why?
| | Child Behavior | 1 | 2017 | 247 | 0.030 |
Why?
| | International Agencies | 1 | 2014 | 35 | 0.030 |
Why?
| | Apolipoproteins | 1 | 2014 | 33 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 886 | 0.030 |
Why?
| | Societies, Scientific | 1 | 2014 | 51 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 207 | 0.030 |
Why?
| | Adolescent Medicine | 1 | 2014 | 36 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2015 | 564 | 0.030 |
Why?
| | Pressure | 1 | 2014 | 222 | 0.030 |
Why?
| | Patient Care Team | 1 | 2019 | 627 | 0.030 |
Why?
| | Nutrition Policy | 1 | 2014 | 58 | 0.030 |
Why?
| | China | 1 | 2014 | 217 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2017 | 412 | 0.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 251 | 0.030 |
Why?
| | Risk | 1 | 2016 | 904 | 0.030 |
Why?
| | Primary Prevention | 1 | 2015 | 196 | 0.030 |
Why?
| | Fibrinogen | 1 | 2014 | 168 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 843 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2018 | 648 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2014 | 189 | 0.020 |
Why?
| | American Heart Association | 1 | 2014 | 306 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2045 | 0.020 |
Why?
| | Genotype | 2 | 2007 | 1919 | 0.020 |
Why?
| | Quality Improvement | 1 | 2019 | 1152 | 0.020 |
Why?
| | Pulsatile Flow | 1 | 2010 | 60 | 0.020 |
Why?
| | Animals | 1 | 2012 | 36768 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1294 | 0.020 |
Why?
| | Arm | 1 | 2010 | 104 | 0.020 |
Why?
| | Elasticity | 1 | 2010 | 197 | 0.020 |
Why?
| | South Carolina | 1 | 2008 | 39 | 0.020 |
Why?
| | Lipoproteins, HDL | 1 | 2008 | 77 | 0.020 |
Why?
| | Nutrition Therapy | 1 | 2008 | 36 | 0.020 |
Why?
| | Models, Biological | 1 | 2015 | 1769 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2008 | 117 | 0.020 |
Why?
| | Leg | 1 | 2010 | 236 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 9 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 52 | 0.020 |
Why?
| | Pancreatic Function Tests | 1 | 2005 | 4 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 309 | 0.010 |
Why?
| | C-Peptide | 1 | 2005 | 163 | 0.010 |
Why?
| | Glucose Tolerance Test | 1 | 2005 | 364 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2677 | 0.010 |
Why?
| | Mother-Child Relations | 1 | 2004 | 137 | 0.010 |
Why?
| | Population Surveillance | 1 | 2006 | 470 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2008 | 925 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1309 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1458 | 0.010 |
Why?
| | Pregnancy | 1 | 2006 | 6731 | 0.010 |
Why?
|
|
Wadwa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|